https://www.yiliao.com/index.php?action=history&feed=atom&title=RP2D
RP2D - 版本历史
2026-04-09T16:21:51Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=RP2D&diff=316173&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-02T18:34:57Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>RP2D</strong>（Recommended Phase 2 Dose，推荐 II 期剂量）是临床试验 I 期阶段最重要的决策终点，指确定用于后续 II 期或 III 期关键临床试验的药物剂量。传统上，RP2D 通常被设定为接近<strong>最大耐受剂量 (MTD)</strong> 的水平，即在不可接受的毒性出现前的最高剂量。然而，随着靶向治疗和免疫疗法（如 PD-1、ADC）的兴起，药物疗效不再总是与剂量呈线性正相关，盲目追求高剂量可能导致不必要的毒性。因此，现代药物开发的 RP2D 确定越来越强调<strong>最佳生物学剂量 (OBD)</strong>，需综合考量安全性、药代动力学 (PK)、药效学 (PD) 及初步疗效数据。FDA 近期推行的 <strong>Project Optimus</strong> 计划正是为了改革肿瘤药物的剂量优化策略，避免“耐受即通过”的粗放模式。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">RP2D</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Recommended Phase 2 Dose (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="width: 100px; height: 100px; background-color: #e2e8f0; border-radius: 50%; margin: 0 auto; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em;"><br />
[剂量曲线]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心目标：平衡疗效与毒性</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">术语参数</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">确定阶段</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Phase I (剂量扩展期)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">关键依据</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">安全性 (DLT), PK/PD</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">相关指标</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">MTD, OBD, DLT</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">监管热点</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Project Optimus (FDA)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">统计设计</th><br />
<td style="padding: 6px 12px; color: #0f172a;">3+3, CRM, BOIN</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">决策逻辑：如何找到“黄金剂量”？</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
RP2D 的确定通常经历“剂量递增 (Escalation)”和“剂量扩展 (Expansion)”两个步骤。根据药物类型的不同，决策逻辑存在显著差异：<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<br />
<br />
[Image of dose response curve]<br />
<br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">药物类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 35%;">传统化疗 (Cytotoxic)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">靶向/免疫 (Targeted/IO)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">基本假设</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">剂量越高，杀伤力越强。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">受体占有率饱和后，增量不增效。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">RP2D 定义</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通常 = <strong>MTD</strong> (最大耐受剂量)。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通常 < <strong>MTD</strong>，称为 <strong>OBD</strong> (最佳生物学剂量)。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; background-color: #eff6ff;">典型设计</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;">3+3 设计 (简单、保守)。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;">BOIN, CRM (贝叶斯模型导向)。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<br />
<div style="display: flex; flex-wrap: wrap; gap: 20px; margin: 20px 0;"><br />
<br />
<div style="flex: 1; min-width: 280px; background-color: #fff1f2; border-left: 5px solid #e11d48; padding: 15px; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #9f1239; font-size: 1.05em;">DLT (剂量限制性毒性)</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.9em; color: #334155;"><br />
指在 I 期试验中出现的严重不良事件（如 3-4 级中性粒细胞减少、3 级肝毒性），该事件阻止了剂量继续递增。RP2D 必须设定在导致 < 33% 患者出现 DLT 的剂量水平之下。<br />
</p><br />
</div><br />
<br />
<div style="flex: 1; min-width: 280px; background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.05em;">Project Optimus</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.9em; color: #334155;"><br />
<strong>FDA 肿瘤卓越中心 (OCE)</strong> 发起的倡议，要求药企在早期试验中对比多个剂量组（Randomized Dose Finding），而非仅寻找 MTD，以改善上市后药物的耐受性。<br />
</p><br />
</div><br />
<br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Le Tourneau C, Lee JJ, Siu LL. (2009).</strong> <em>Dose escalation methods in phase I cancer clinical trials.</em> <strong>[[Journal of the National Cancer Institute]]</strong>. <br><br />
<span style="color: #475569;">[点评]：经典综述，详细比较了基于规则（如 3+3）和基于模型（如 CRM）的剂量探索方法的优劣。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Postel-Vinay S, et al. (2014).</strong> <em>Phase I trials in the era of targeted therapy: strict conventional rules no longer apply.</em> <strong>[[Nature Reviews Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：阐述了为何靶向药不能沿用化疗时代的 MTD 逻辑，提出了基于靶点抑制率（PD 标志物）确定 RP2D 的新思路。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Shah M, Rahman A, Theocharis T, et al. (2021).</strong> <em>The FDA’s Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology.</em> <strong>[[Clinical Cancer Research]]</strong>. <br><br />
<span style="color: #475569;">[点评]：来自 FDA 官方的声音，解释了监管机构为何开始拒绝仅基于 MTD 申报的药物，强调剂量优化的必要性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
临床试验设计 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关键指标</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MTD]] (最大耐受剂量) • [[DLT]] (剂量限制性毒性) • [[AUC]] (暴露量)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">统计模型</td><br />
<td style="padding: 10px 15px; color: #334155;">[[3+3设计]] • [[BOIN]] (贝叶斯最优区间) • [[CRM]] (连续重评估)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">相关机构</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FDA]] (Project Optimus) • [[NCI]] (美国国家癌症研究所)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020